Trial Profile
A Multi-Center, Randomized, Double-Blind, Parallel Comparative, Phase II Study to Evaluate the Efficacy and Safety of Intravenous Infusion With Nemonoxacin Versus Moxifloxacin in Treating Adult Patients With Community-Acquired Pneumonia (CAP)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Nemonoxacin (Primary) ; Moxifloxacin
- Indications Bacterial infections; Community-acquired pneumonia
- Focus Therapeutic Use
- Sponsors TaiGen Biotechnology
- 20 Sep 2013 New source identified and integrated (ClinicalTrials.gov: NCT01944774)
- 16 May 2013 Status changed from planning to recruiting, based on information in a TaiGen Biotechnology media release.
- 12 Dec 2011 New trial record